Jamaica Plain, MA, United States of America

Wayne I Lencer

USPTO Granted Patents = 16 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 2.7

ph-index = 6

Forward Citations = 587(Granted Patents)

Location History:

Jamaica Plains, MA (US) (2001 - 2002)
Jamaica Plain, MA (US) (1999 - 2023)

Company Filing History:

7 out of 1,036

Children's Medical Center Corporation

patents

4 out of 1,373

The Brigham and Women's Hospital, Inc.

Children's Medical Corporation

patent

6. 3 out of 832,761

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12383606 - Short chain ceramide-based lipids and uses thereof (2025-08-12),

2. 12296016 - Ceramide-like lipid-based delivery vehicles and uses thereof (2025-05-13),

3. 11771771 - Ceramide-like lipid-based delivery vehicles and uses thereof (2023-10-03),

4. 11559568 - Short chain ceramide-based lipids and uses thereof (2023-01-24),

5. 10806793 - Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids (2020-10-20),

6. 10765757 - Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids (2020-09-08),

7. 9457097 - Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids (2016-10-04),

8. 9072728 - Treatment of severe distal colitis (2015-07-07),

9. 7547436 - Receptor specific transepithelial transport of therapeutics (2009-06-16),

10. 7067129 - Receptor specific transepithelial transport in therapeutics (2006-06-27),

11. 7060274 - Receptor specific transepithelial transport of therapeutics (2006-06-13),

12. 6495567 - Triaryl methane compounds and their use in the treatment of diarrhea and scours (2002-12-17),

13. 6485726 - Receptor specific transepithelial transport of therapeutics (2002-11-26),

14. 6291449 - Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours (2001-09-18),

15. 6030613 - Receptor specific transepithelial transport of therapeutics (2000-02-29),

Title: Wayne I Lencer: Innovator in Lipid-Based Delivery Systems

Introduction

Wayne I Lencer is a prominent inventor based in Jamaica Plain, MA (US). He has made significant contributions to the field of lipid-based delivery systems, holding a total of 16 patents. His work focuses on innovative methods for delivering therapeutic agents, which have the potential to improve treatment outcomes for various diseases.

Latest Patents

Lencer's latest patents include groundbreaking inventions such as "Short chain ceramide-based lipids and uses thereof." This patent describes delivery vehicles that comprise a glycosphingolipid and an agent to be delivered. The glycosphingolipid can effectively transport therapeutic agents to cells or cellular compartments, enhancing their efficacy. Another notable patent is "Ceramide-like lipid-based delivery vehicles and uses thereof," which outlines delivery vehicles that utilize ceramides to transport agents. These inventions aim to provide longer half-lives for agents compared to those delivered alone, showcasing Lencer's innovative approach to drug delivery.

Career Highlights

Throughout his career, Wayne I Lencer has worked with esteemed organizations such as Children's Medical Center Corporation and Brigham and Women's Hospital, Inc. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to significant advancements in medical research.

Collaborations

Lencer has collaborated with notable colleagues, including Daniel J F Chinnapen and Richard S Blumberg. These partnerships have fostered a collaborative environment that encourages innovation and the development of new therapeutic strategies.

Conclusion

Wayne I Lencer's contributions to lipid-based delivery systems have positioned him as a key figure in the field of medical innovation. His patents reflect a commitment to improving therapeutic delivery methods, ultimately benefiting patients and advancing medical science.

This text is generated by artificial intelligence and may not be accurate.